Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06390423 · ClinicalTrials.gov registry record
Passive Leg Raise and Mini-fluid Challenge Effect on Various Cardiac Output Surrogates for Fluid Responsiveness
A clinical trial of Fluid Responsiveness, sponsored by CentraCare.
- Recruiting
- Registry status
- 64
- Enrollment target
- 1
- Study location
NCT06390423: Recruiting study of Fluid Responsiveness, sponsored by CentraCare.
NCT06390423 is a study of Fluid Responsiveness that is actively recruiting participants, run by CentraCare. The registered enrollment target is 64 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06390423, a study of Fluid Responsiveness, is actively recruiting participants, sponsored by CentraCare.
- RECRUITING
- Registry status
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
In the critically ill population, fluid administration in an unstable patient is perhaps the most common intervention that is performed. Uncorrected hypovolemia with inappropriate vasopressors lead to organ hypoperfusion where as overzealous fluid administration especially in ARDS (Adult respiratory distress syndrome) can increase mortality. It has been estimated that only 50% of hemodynamically unstable critically ill patients are volume responsive, hence dynamic assessment of preload responsiveness has been proposed to better identify those individuals who would benefit from fluid bolus.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Passive leg raise, SVI via bioreactance, Echo based VTI
Study Locations (1)
Minnesota
- St Cloud Hospital - Saint Cloud
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2025-06 |
What NCT06390423 shows while recruiting
NCT06390423 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.
The record links to 1 condition, with Fluid Responsiveness appearing as the primary indexed condition, and to 1 intervention - of which Passive leg raise, SVI via bioreactance, Echo based VTI is the first listed.
NCT06390423 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06390423 about?
NCT06390423 is a clinical study titled "Passive Leg Raise and Mini-fluid Challenge Effect on Various Cardiac Output Surrogates for Fluid Responsiveness". In the critically ill population, fluid administration in an unstable patient is perhaps the most common intervention that is performed. Uncorrected hypovolemia with inappropriate vasopressors lead to organ hypoperfusion where as overzealous fluid administration especially in ARDS (Adult respiratory...
What is the current status of trial NCT06390423?
This trial is currently recruiting. The enrollment target is 64 participants. The study started on 2023-07-01. Estimated completion is 2025-06.
What conditions does trial NCT06390423 study?
This clinical trial studies the following conditions: Fluid Responsiveness.
What interventions are being tested in trial NCT06390423?
The interventions under investigation include: Passive leg raise, SVI via bioreactance, Echo based VTI (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06390423?
This trial is sponsored by CentraCare, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06390423 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI